scispace - formally typeset
Open AccessJournal ArticleDOI

Aliskiren, a novel orally effective renin inhibitor, provides antihypertensive efficacy and placebo-like tolerability similar to an at1-receptor blocker in hypertensive patients

Reads0
Chats0
About
This article is published in American Journal of Hypertension.The article was published on 2004-05-01 and is currently open access. It has received 22 citations till now. The article focuses on the topics: Aliskiren & Renin inhibitor.

read more

Citations
More filters
Journal ArticleDOI

Renin inhibition with aliskiren: where are we now, and where are we going?

TL;DR: The potential of renin inhibition must be viewed in the context of the remarkable efficacy of both angiotensin-converting enzyme (ACE) inhibition and angiotENSin receptor blockers (ARBs) and the therapeutic implications for both the renin inhibitor employed alone or the renIn inhibitor combined with an ACE inhibitor or ARB.
Journal ArticleDOI

Bio-functionalities of proteins derived from marine algae — A review

TL;DR: In this review, identified bioactivities and potentialities of marine algal protein sources will be discussed for future pharmaceutical, nutraceutical and cosmeceutical applications.
Journal ArticleDOI

Binding thermodynamics of substituted diaminopyrimidine renin inhibitors.

TL;DR: High-throughput screening efforts identified a small molecule renin inhibitor with a core substituted diaminopyrimidine ring that could be useful for the treatment of hypertension and suggested molecular alterations to improve binding affinity from both thermodynamic and structural perspectives.
Journal Article

Aliskiren – an orally active renin inhibitor. Review of pharmacology, pharmacodynamics, kinetics, and clinical potential in the treatment of hypertension

TL;DR: Aliskiren is the first in a new class of orally active, non-peptide, low molecular weight renin inhibitors, and so far the only renin inhibitor that has progressed to phase III clinical trials.
Related Papers (5)